What is the inhibin A test used for?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is the Inhibin A Test Used For?

Inhibin A is primarily used as a second-trimester maternal serum marker for prenatal screening of Down syndrome (trisomy 21), where it is incorporated into the quadruple screen test performed between 15-20 weeks of gestation. 1, 2

Primary Clinical Application: Down Syndrome Screening

The quadruple marker screen (also called "Quad screen") combines inhibin A with alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), and unconjugated estriol (uE3) to assess the risk of fetal Down syndrome. 1, 2, 3

Detection Performance

  • The quadruple screen detects approximately 75% of Down syndrome cases in women younger than 35 years and over 80% in women 35 years and older, at a 5% false-positive rate 2, 3
  • Adding inhibin A to the triple screen (AFP, hCG, uE3) increases the detection rate by approximately 5-10% compared to the triple screen alone 2, 3

Optimal Testing Window

  • The test should be performed between 16-18 weeks gestation (optimal window), with an acceptable range of 15-20 weeks 2
  • Accurate gestational age dating by ultrasound is essential for proper interpretation 2

Inhibin A Levels in Down Syndrome

In Down syndrome pregnancies, maternal serum inhibin A levels are approximately 2-fold higher (elevated) compared to chromosomally normal pregnancies during the second trimester. 3, 4

  • The median inhibin A level in Down syndrome pregnancies is approximately 2.0 multiples of the median (MoM) 3
  • This elevation appears to reflect increased placental production rather than fetal sources 4

Additional Clinical Context

Other Tumor Markers in Ovarian Cancer

While inhibin A is primarily a prenatal screening marker, inhibin may also be used as a tumor marker in certain ovarian cancers (particularly granulosa cell tumors), though this is a separate clinical application from prenatal screening. 1

Important Covariates Affecting Interpretation

Risk calculations must be adjusted for several maternal factors that affect inhibin A levels: 2

  • Maternal weight
  • Race/ethnicity
  • Insulin-dependent diabetes
  • Number of fetuses (singleton vs. multiple gestation)
  • Fetal gender (female fetuses associated with slightly higher levels) 5

Critical Implementation Points

Laboratory Standardization

  • The inhibin A assay is standardized against the First International Standard for Inhibin (Code 91/624) 1
  • Results can be reported in pg/mL or IU/mL 1
  • Significant variability exists between different assay lots (up to 30%), requiring laboratories to establish and monitor their own gestational age-specific medians 6

Common Pitfalls to Avoid

Technical errors that compromise screening accuracy include: 2

  • Failing to use ultrasound dating for gestational age determination
  • Not reinterpreting results when revised gestational age dates become available
  • Using singleton cutoffs for twin pregnancies
  • Inadequate counseling about the screening nature of the test (not diagnostic)

Clinical Management After Abnormal Results

When the quadruple screen indicates increased risk for Down syndrome, the next step is genetic counseling and offering diagnostic testing (amniocentesis) rather than repeating the screening test. 2

  • Women 35 years and older should be counseled about the option of diagnostic testing (CVS or amniocentesis) in addition to or instead of screening 2
  • A positive screen does not diagnose Down syndrome—it only indicates increased risk requiring further evaluation 2

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.